Trial Profile
Effects of a Pioglitazone/Metformin Fixed Combination in Comparison to Metformin in Combination With Glimepiride on Diabetic Dyslipidemia.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Metformin/pioglitazone (Primary) ; Glimepiride; Metformin
- Indications Dyslipidaemias; Type 2 diabetes mellitus
- Focus Pharmacodynamics; Registrational; Therapeutic Use
- Sponsors Takeda Pharma
- 26 Jun 2010 Results presented at the 70th Annual Scientific Sessions of the American Diabetes Association.
- 26 Jun 2010 Inflammatory marker results presented at the 70th Annual Scientific Sessions of the American Diabetes Association.
- 21 Aug 2009 Planned number of patients changed from 300 to 305 as reported by ClinicalTrials.gov.